Mirati Therapeutics
9363 Towne Centre Drive
Suite 200
San Diego
California
92121
United States
Tel: 858-535-2075
Website: http://mirati.com/
140 articles with Mirati Therapeutics
-
Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources
8/15/2019
Ms. Gizzi will be responsible for all aspects of the Company's human resources operations and strategy, including overseeing the planning, development, implementation and administration of Mirati's human resources programs.
-
Mirati Therapeutics Reports Second Quarter 2019 Financial Results
8/5/2019
Completed a successful public offering of common stock in June that provided net cash proceeds of $219.9 million.
-
Preclinical data has shown that the combination of a KRAS G12C inhibitor with a SHP2 inhibitor results in increased anti-tumor activity based on their complementary mechanisms of action.
-
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
7/9/2019
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO155, Novartis' investigational SHP2 inhibitor, in patients with advanced solid tumors that harbor KRAS G12C mutations.
-
Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors
7/1/2019
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Dr. Julie Cherrington, Ph.D. to its Board of Directors, effective June 27, 2019.
-
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares - June 27, 2019
6/27/2019
Mirati Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 2,415,000 shares of its common stock at a public offering price of $97.00 per share.
-
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock - June 25, 2019
6/25/2019
Mirati Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,100,000 shares of its common stock at a price to the public of $97.00 per share.
-
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock On June 24, 2019
6/24/2019
Mirati Therapeutics, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.
-
Mirati Therapeutics Announces Proposed Public Offering of Common Stock - June 24, 2019
6/24/2019
Mirati Therapeutics, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.
-
Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference
5/30/2019
Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will present a corporate overview at the conference.
-
Mirati Therapeutics Reports First Quarter 2019 Financial Results
4/29/2019
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results for the first quarter ended March 31, 2019.
-
Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
4/1/2019
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London, England on Monday, April 8th at 11:30am BST/6:30am ET/3:30am PT. Christopher C. LeMasters, Chief Business Officer, will provide a corporate update at the conference.
-
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
3/5/2019
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences.
-
Mirati Therapeutics Reports Fourth Quarter Financial Results
2/28/2019
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full-year ended December 31, 2018.
-
Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors
2/19/2019
Mirati Therapeutics, Inc., a clinical stage targeted oncology company, announced the appointment of Faheem Hasnain as Chairman of the Board, effective February 15, 2019.
-
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
2/7/2019
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14th at 11:00 a.m. ET/ 8:00 a.m. PT.
-
Mirati Therapeutics Announces Closing Of Public Offering Of 1,854,838 Shares of Its Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
1/22/2019
Mirati Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common stock at a public offering price of $62.00 per share.
-
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock - January 16, 2019
1/17/2019
Mirati Therapeutics, Inc. announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share
-
Lonza Announces Initiation of S&P Credit Rating with Investment Grade of BBB+ and Stable Outlook
1/17/2019
Lonza announced that Standard & Poor's (S&P) assigned a BBB+ credit rating with stable outlook to Lonza.
-
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock - January 16, 2019
1/16/2019
Mirati Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, $75.0 million of shares of its common stock in an underwritten public offering.